ZVRA Zevra Therapeutics, Inc.

BUSINESS SUMMARY

Zevra Therapeutics is a rare-disease commercial-stage pharmaceutical company built around two FDA-approved products and an in-development pipeline:

• OLPRUVA (sodium phenylbutyrate) — approved for urea-cycle disorders (UCD), a group of rare metabolic conditions where the body cannot process nitrogen waste
• MIPLYFFA (arimoclomol) — approved September 2024 for Niemann-Pick disease type C, a fatal lysosomal storage disorder. The company acquired this asset from Orphazyme through bankruptcy in 2022 and successfully completed development to FDA approval

Revenue is per-prescription product sales through specialty-pharmacy distribution, plus the rare-disease priority-review-voucher (PRV) that comes with first-in-indication approvals (the MIPLYFFA approval generated a PRV that Zevra can sell or use).

Zevra also holds smaller pipeline candidates and operates a small specialty-distribution arm. The strategic profile is multi-product rare-disease pharma, unusual at this small-cap scale.

MARKET OPPORTUNITY

The rare-disease pharmaceutical market is high-priced and policy-protected:

• Urea-cycle disorders — ~3,000 US patients; OLPRUVA competes against generic sodium phenylbutyrate alternatives where Zevra's branded delivery format is the differentiator
• Niemann-Pick type C — fewer than 200 US patients but per-patient annual cost exceeds $500K; MIPLYFFA is the first FDA-approved disease-specific therapy
• Pipeline expansion — additional rare-disease indications and label-expansion opportunities

Macro context: the revenue growth of 351% YoY reflects the MIPLYFFA approval ramp combined with continued OLPRUVA prescribing. The headline rate is launch-S-curve flatter than steady-state.

REVENUE QUALITY

The economics reflect a multi-product rare-disease pharma:

• Gross margin 85% — exceptional, typical for orphan-drug pricing
• Operating margin — improving but still pressured by sales-force-buildout for MIPLYFFA launch
• Revenue $106M TTM — small absolute scale but two FDA-approved products at this size is rare
• P/S ~5.6 — premium reflecting rare-disease-pharma valuation premium plus pipeline-NPV optimism

COMPETITIVE ADVANTAGE

The defensible asset is the FDA-approval-and-orphan-drug-exclusivity package plus the multi-product portfolio:

• First-in-indication FDA approval for MIPLYFFA in Niemann-Pick type C — 7-year orphan-drug exclusivity
• OLPRUVA branded-formulation positioning versus generic sodium phenylbutyrate
• Rare-disease commercial-team relationships with the small specialist-physician community treating UCD and NPC
• Priority-review voucher monetization — PRV from the MIPLYFFA approval can be sold (typically $80-100M)

What it is not: a moat against larger rare-disease specialty pharma (Ultragenyx, BioMarin, Travere) on adjacent indications. Zevra's wedge is current FDA approvals plus the operational discipline to monetize PRVs.

GROWTH THESIS

Three things have to work:

1. MIPLYFFA prescription ramp continues — the multi-quarter post-launch S-curve drives near-term revenue
2. Pipeline-asset development — additional rare-disease candidates need to advance toward approvability
3. PRV monetization timing — when and at what price the priority-review voucher monetizes affects discretely the cash-position

KEY RISKS

Three specific risks:

1. MIPLYFFA launch slower-than-expected. Niemann-Pick type C is so rare that prescription growth quarter-over-quarter is volatile; missing launch milestones would compress the equity story.

2. OLPRUVA generic pressure. Generic sodium phenylbutyrate alternatives exist; OLPRUVA's branded-pricing premium depends on clinical-and-formulation differentiation that competitive pricing could erode.

3. Pipeline-execution risk. The pipeline is the multi-year-value driver beyond the two approved products; clinical setbacks compound.

VERDICT

The 82.7/100 score captures the genuine quality of a multi-product rare-disease commercial-stage pharma — a profile rare at this small-cap scale. The MIPLYFFA approval combined with the PRV monetization optionality provide unusual near-term value drivers.

For investors who want rare-disease specialty pharma exposure with multiple FDA approvals at small-cap scale, ZVRA is one of the cleaner names with real multi-product portfolio quality. For investors avoiding small-cap rare-disease execution risk, the launch-and-execution dependence is the legitimate concern.

The single metric to watch next is MIPLYFFA prescription count and revenue trajectory quarter-over-quarter. Continued compounding signals the launch is on track.